CTOs on the Move

Sigilon

www.sigilon.com

 
Sigilon Therapeutics’ mission is to create immune-protected, engineered human cells that restore normal physiology in a wide range of diseases without generating fibrosis or immune rejection, liberating patients from challenges associated with serious chronic diseases. We're based in Cambridge, Mass.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.sigilon.com
  • 100 Binney Street Suite 600
    Cambridge, MA USA 02142
  • Phone: 617.336.7540

Executives

Name Title Contact Details
Sarah Yuan
Chief Technical Operations Officer Profile
Martha Rook
Chief Technical Operations Officer Profile
Susan Drapeau
Vice President and Head of Device and Delivery Engineering Profile

Funding

Sigilon raised $80.3M on 03/17/2020

Similar Companies

Gen9

Gen9 is the premier next-generation gene synthesis company focused on high-quality, high-throughput, automated production of DNA constructs. The Gen9 technology allows for the lowest-cost and highest-quality DNA constructs commercially available. Founded by world leaders in synthetic biology, Gen9 aims to ensure the constructive application of synthetic biology in industries ranging from enzyme and chemical production to pharmaceuticals and biofuels. Gen9 is powering the synthetic biology revolution from our headquarters in Cambridge, Mass

Enthrive

Enthrive is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Odyssey Research Services

Odyssey Research Services is a Bismarck, ND-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

T-knife

T-knife Therapeutics is a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, initially focused on T cell receptor (TCR) engineered T cell therapies (TCR-Ts), a modality that holds the potential to generate transformative responses in patients with solid tumors. The Company`s unique approach leverages its proprietary HuTCR mouse platform, a next-generation T cell receptor and epitope discovery engine that produces fully human, tumor-specific TCRs, naturally selected in vivo for optimal affinity and high specificity. T-knife is advancing a portfolio of TCR-T product candidates against targets with high unmet medical need, including cancer testis antigens, oncoviral antigens and commonly shared tumor-driving neoantigens. T-knife was founded by leading T-cell and immunology experts using technology developed at the Max Delbruck Center for Molecular Medicine together with Charité – Universitätsmedizin Berlin.

Geo Digm Corporation

Geo Digm Corporation is a Chanhassen, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.